Products/Prescription medication
Finasteride 1 mg tablets
Finasteride 1 mg is the licensed oral treatment for male androgenetic alopecia and the most extensively studied oral hair loss medication.
Priced after clinical assessmentprescription-only medicine, price confirmed at consultationPricing
This is a prescription-only medicine, so we cannot publish a price against it. UK law restricts advertising prescription-only medicines to the public, and that applies to every provider, not just to us.
How you get your price
- Complete the online assessment. It is free and there is no consultation fee.
- A GMC-registered doctor reviews it and confirms whether this treatment is appropriate for you.
- You receive the full price in writing, including every supply length and any rolling option, plus postage.
- You are charged only if you decide to go ahead. Nobody is charged for being turned down.
One tablet daily. Buying a longer supply lowers the monthly cost, and postage is a flat charge per order within the UK whatever the quantity. Both are set out in your quote.
About this product
Finasteride 1 mg daily is the licensed dose for male pattern hair loss and is supported by long-term follow-up data showing maintenance or improvement in scalp hair density in the majority of treated men. It reduces dihydrotestosterone (DHT), the hormone driving follicular miniaturisation in androgenetic alopecia (suppressing serum DHT by approximately 70 percent per the Kaufman 1998 and Drake 1999 trials). Most men tolerate finasteride well. Sexual side effects (reduced libido, erectile dysfunction, ejaculatory disorders) and mood-related effects (low mood, anxiety, and in rare cases suicidal thoughts) have been reported. The MHRA issued a Drug Safety Update on 29 April 2024 covering these risks and introduced patient alert cards into finasteride packs alongside updated product information. The MHRA strengthened these warnings further in a Drug Safety Update on 11 May 2026, which also extended precautionary advice to dutasteride. Most side effects resolve on stopping treatment, but sexual dysfunction that may persist after discontinuation has been reported. We review tolerability at each follow-up and patients can stop at any time; any new mood changes or persistent sexual symptoms should be reported promptly. Women who are or may become pregnant must not handle crushed or broken finasteride tablets because of a small risk of harm to a developing male fetus; the whole, film-coated tablet poses no such risk during normal handling.
How it works
Finasteride is a selective inhibitor of 5-alpha-reductase type II, the enzyme that converts testosterone to DHT in scalp and prostate tissue. Reducing scalp DHT reduces follicular miniaturisation, allowing affected follicles to recover.
Who this product is for
- You are a man with established male pattern hair loss
- You want the most evidence-based oral hair loss treatment
- You are pre or post hair transplant and want to protect graft survival
- You have no contraindications and are willing to review tolerability with your clinician
Important information
This is a prescription-only medication. WMG Meds is an online assessment service operating under Westminster Medical Group (CQC-registered, Harley Street). Prescriptions are issued by a GMC-registered doctor after asynchronous review of your questionnaire and declared medical history. Suitability, dose and strength are decided by your clinician on a case-by-case basis. We are not a pharmacy and do not dispense in-clinic: your prescription is fulfilled and delivered by our partner pharmacy.
Prescribed under: Dr Sebastian Deme (Medical Director, GMC 7130749) or Dr Grahame Shaw (GMC 7460905), both on the GMC Register and clinically responsible for prescribing decisions on this product. Meet the team.
If you experience side effects or have any clinical concerns, contact us via the enquiry form or call 020 3239 3378. For urgent symptoms please contact your GP, NHS 111, or 999.
Safety information and regulatory updates
Please read the following before starting Finasteride 1 mg tablets. Your clinician will discuss any concerns at clinical review and you can stop treatment at any time.
MHRA Drug Safety Updates and contraindications
- MHRA Drug Safety Update 29 April 2024 and 11 May 2026: risk of psychiatric reactions including depression, anxiety and suicidal thoughts; risk of sexual dysfunction (reduced libido, erectile dysfunction, ejaculatory disorders) which may persist after discontinuation. Patient alert cards now included in finasteride packs.
- Not licensed for women. Women who are or may become pregnant must not handle crushed or broken tablets due to risk of harm to a developing male foetus. Whole film-coated tablets pose no skin-absorption risk during normal handling (Propecia SmPC).
- Stop and seek medical advice if mood changes, suicidal thoughts or new sexual symptoms develop.
Patient Information Leaflet
The official UK Patient Information Leaflet (PIL) on the eMC, the MHRA-affiliated electronic Medicines Compendium.
Yellow Card scheme
Report any suspected side effects of Finasteride 1 mg tablets to the MHRA via the Yellow Card scheme. Reporting helps the MHRA monitor medicines safety in the UK.
Other medications
Compare against the rest of the range.
Who is behind this prescription
Your prescription for finasteride 1 mg tablets is not issued by an algorithm.
It is reviewed and signed by a GMC-registered doctor working under Westminster Medical Group, the CQC-registered clinical provider at 134 Harley Street, London W1G 7JY. That is a working clinic with a phone number, not a registered office. You are welcome to ring it.
- Dr Grahame Shaw Hair Transplant Doctor GMC 7460905 · verifiable on the GMC register
- Dr Sebastian Deme Medical Director and Lead Hair Transplant Surgeon GMC 7130749 · verifiable on the GMC register
Company No. 11237471. WMG Meds does not hold a pharmacy premises licence and does not dispense in clinic; medication is dispensed by our UK pharmacy partner and posted.